20/20 Biolabs Inc. (AIDX) Stock Competitors & Peer Comparison
See (AIDX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AIDX | $0.60 | +1.58% | 3.4M | -1.13 | -$0.53 | N/A |
| HCA | $391.68 | +1.22% | 86.9B | 13.53 | $28.96 | +0.77% |
| THC | $189.00 | +2.75% | 16.2B | 10.90 | $17.24 | N/A |
| DVA | $217.04 | +1.72% | 13.9B | 18.49 | $11.73 | N/A |
| SOLV | $79.53 | +2.07% | 13.8B | 12.75 | $6.24 | N/A |
| FMS | $23.24 | -0.04% | 12.5B | 9.23 | $2.52 | +3.73% |
| EHC | $101.33 | +1.61% | 10.1B | 17.81 | $5.69 | +0.74% |
| ENSG | $163.05 | -1.62% | 9.5B | 23.63 | $6.90 | +0.16% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| UHS | $145.69 | +0.85% | 9.1B | 6.46 | $22.54 | +0.55% |
Stock Comparison
AIDX vs HCA Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, HCA has a market cap of 86.9B. Regarding current trading prices, AIDX is priced at $0.60, while HCA trades at $391.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas HCA's P/E ratio is 13.53. In terms of profitability, AIDX's ROE is +1.12%, compared to HCA's ROE of -1.23%. Regarding short-term risk, AIDX is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check HCA's competition here
AIDX vs THC Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, THC has a market cap of 16.2B. Regarding current trading prices, AIDX is priced at $0.60, while THC trades at $189.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas THC's P/E ratio is 10.90. In terms of profitability, AIDX's ROE is +1.12%, compared to THC's ROE of +0.41%. Regarding short-term risk, AIDX is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check THC's competition here
AIDX vs DVA Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, DVA has a market cap of 13.9B. Regarding current trading prices, AIDX is priced at $0.60, while DVA trades at $217.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas DVA's P/E ratio is 18.49. In terms of profitability, AIDX's ROE is +1.12%, compared to DVA's ROE of -1.33%. Regarding short-term risk, AIDX is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check DVA's competition here
AIDX vs SOLV Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, SOLV has a market cap of 13.8B. Regarding current trading prices, AIDX is priced at $0.60, while SOLV trades at $79.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas SOLV's P/E ratio is 12.75. In terms of profitability, AIDX's ROE is +1.12%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, AIDX is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check SOLV's competition here
AIDX vs FMS Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, FMS has a market cap of 12.5B. Regarding current trading prices, AIDX is priced at $0.60, while FMS trades at $23.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas FMS's P/E ratio is 9.23. In terms of profitability, AIDX's ROE is +1.12%, compared to FMS's ROE of +0.07%. Regarding short-term risk, AIDX is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check FMS's competition here
AIDX vs EHC Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, EHC has a market cap of 10.1B. Regarding current trading prices, AIDX is priced at $0.60, while EHC trades at $101.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas EHC's P/E ratio is 17.81. In terms of profitability, AIDX's ROE is +1.12%, compared to EHC's ROE of +0.25%. Regarding short-term risk, AIDX is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check EHC's competition here
AIDX vs ENSG Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, ENSG has a market cap of 9.5B. Regarding current trading prices, AIDX is priced at $0.60, while ENSG trades at $163.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas ENSG's P/E ratio is 23.63. In terms of profitability, AIDX's ROE is +1.12%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, AIDX is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check ENSG's competition here
AIDX vs OSH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, AIDX is priced at $0.60, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas OSH's P/E ratio is -17.65. In terms of profitability, AIDX's ROE is +1.12%, compared to OSH's ROE of +4.64%. Regarding short-term risk, AIDX is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check OSH's competition here
AIDX vs UHS Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, UHS has a market cap of 9.1B. Regarding current trading prices, AIDX is priced at $0.60, while UHS trades at $145.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas UHS's P/E ratio is 6.46. In terms of profitability, AIDX's ROE is +1.12%, compared to UHS's ROE of +0.21%. Regarding short-term risk, AIDX is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check UHS's competition here
AIDX vs CHE Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CHE has a market cap of 6.1B. Regarding current trading prices, AIDX is priced at $0.60, while CHE trades at $463.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CHE's P/E ratio is 21.38. In terms of profitability, AIDX's ROE is +1.12%, compared to CHE's ROE of +0.25%. Regarding short-term risk, AIDX is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check CHE's competition here
AIDX vs LHCG Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, AIDX is priced at $0.60, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas LHCG's P/E ratio is 82.83. In terms of profitability, AIDX's ROE is +1.12%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, AIDX is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check LHCG's competition here
AIDX vs MMED Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, MMED has a market cap of 4B. Regarding current trading prices, AIDX is priced at $0.60, while MMED trades at $14.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas MMED's P/E ratio is -9.79. In terms of profitability, AIDX's ROE is +1.12%, compared to MMED's ROE of -0.09%. Regarding short-term risk, AIDX is more volatile compared to MMED. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check MMED's competition here
AIDX vs LFST Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, LFST has a market cap of 4B. Regarding current trading prices, AIDX is priced at $0.60, while LFST trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas LFST's P/E ratio is 163.77. In terms of profitability, AIDX's ROE is +1.12%, compared to LFST's ROE of +0.02%. Regarding short-term risk, AIDX is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check LFST's competition here
AIDX vs BKD Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, BKD has a market cap of 3.7B. Regarding current trading prices, AIDX is priced at $0.60, while BKD trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas BKD's P/E ratio is -27.06. In terms of profitability, AIDX's ROE is +1.12%, compared to BKD's ROE of +401.19%. Regarding short-term risk, AIDX is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check BKD's competition here
AIDX vs OPCH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, OPCH has a market cap of 3.4B. Regarding current trading prices, AIDX is priced at $0.60, while OPCH trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas OPCH's P/E ratio is 12.69. In terms of profitability, AIDX's ROE is +1.12%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, AIDX is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check OPCH's competition here
AIDX vs AMED Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, AIDX is priced at $0.60, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AMED's P/E ratio is 39.30. In terms of profitability, AIDX's ROE is +1.12%, compared to AMED's ROE of +0.09%. Regarding short-term risk, AIDX is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check AMED's competition here
AIDX vs NHC Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, NHC has a market cap of 3.2B. Regarding current trading prices, AIDX is priced at $0.60, while NHC trades at $206.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas NHC's P/E ratio is 29.47. In terms of profitability, AIDX's ROE is +1.12%, compared to NHC's ROE of +0.12%. Regarding short-term risk, AIDX is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check NHC's competition here
AIDX vs ACHC Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, ACHC has a market cap of 2.5B. Regarding current trading prices, AIDX is priced at $0.60, while ACHC trades at $27.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas ACHC's P/E ratio is 13.74. In terms of profitability, AIDX's ROE is +1.12%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, AIDX is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check ACHC's competition here
AIDX vs ASTH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, ASTH has a market cap of 2.2B. Regarding current trading prices, AIDX is priced at $0.60, while ASTH trades at $44.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas ASTH's P/E ratio is 30.07. In terms of profitability, AIDX's ROE is +1.12%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, AIDX is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check ASTH's competition here
AIDX vs SGRY Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, SGRY has a market cap of 2.1B. Regarding current trading prices, AIDX is priced at $0.60, while SGRY trades at $15.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas SGRY's P/E ratio is 40.56. In terms of profitability, AIDX's ROE is +1.12%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, AIDX is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check SGRY's competition here
AIDX vs SEM Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, SEM has a market cap of 2.1B. Regarding current trading prices, AIDX is priced at $0.60, while SEM trades at $16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas SEM's P/E ratio is 15.46. In terms of profitability, AIDX's ROE is +1.12%, compared to SEM's ROE of +0.08%. Regarding short-term risk, AIDX is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check SEM's competition here
AIDX vs MD Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, MD has a market cap of 2B. Regarding current trading prices, AIDX is priced at $0.60, while MD trades at $24.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas MD's P/E ratio is 11.54. In terms of profitability, AIDX's ROE is +1.12%, compared to MD's ROE of +0.20%. Regarding short-term risk, AIDX is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check MD's competition here
AIDX vs AGL Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AGL has a market cap of 2B. Regarding current trading prices, AIDX is priced at $0.60, while AGL trades at $119.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AGL's P/E ratio is -11.48. In terms of profitability, AIDX's ROE is +1.12%, compared to AGL's ROE of -1.46%. Regarding short-term risk, AIDX is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check AGL's competition here
AIDX vs AVAH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AVAH has a market cap of 1.9B. Regarding current trading prices, AIDX is priced at $0.60, while AVAH trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AVAH's P/E ratio is 12.74. In terms of profitability, AIDX's ROE is +1.12%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, AIDX is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check AVAH's competition here
AIDX vs AMEH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, AIDX is priced at $0.60, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AMEH's P/E ratio is 39.25. In terms of profitability, AIDX's ROE is +1.12%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, AIDX is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check AMEH's competition here
AIDX vs ADUS Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, ADUS has a market cap of 1.8B. Regarding current trading prices, AIDX is priced at $0.60, while ADUS trades at $96.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas ADUS's P/E ratio is 15.05. In terms of profitability, AIDX's ROE is +1.12%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, AIDX is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check ADUS's competition here
AIDX vs HCSG Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, HCSG has a market cap of 1.7B. Regarding current trading prices, AIDX is priced at $0.60, while HCSG trades at $24.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas HCSG's P/E ratio is 19.45. In terms of profitability, AIDX's ROE is +1.12%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, AIDX is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check HCSG's competition here
AIDX vs INNV Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, INNV has a market cap of 1.5B. Regarding current trading prices, AIDX is priced at $0.60, while INNV trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas INNV's P/E ratio is -119.89. In terms of profitability, AIDX's ROE is +1.12%, compared to INNV's ROE of -0.09%. Regarding short-term risk, AIDX is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check INNV's competition here
AIDX vs CMPS Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CMPS has a market cap of 1.4B. Regarding current trading prices, AIDX is priced at $0.60, while CMPS trades at $14.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CMPS's P/E ratio is -8.99. In terms of profitability, AIDX's ROE is +1.12%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, AIDX is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check CMPS's competition here
AIDX vs ARDT Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, ARDT has a market cap of 1.4B. Regarding current trading prices, AIDX is priced at $0.60, while ARDT trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas ARDT's P/E ratio is 5.95. In terms of profitability, AIDX's ROE is +1.12%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, AIDX is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check ARDT's competition here
AIDX vs AMN Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, AIDX is priced at $0.60, while AMN trades at $32.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AMN's P/E ratio is 10.88. In terms of profitability, AIDX's ROE is +1.12%, compared to AMN's ROE of -0.05%. Regarding short-term risk, AIDX is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check AMN's competition here
AIDX vs PNTG Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, PNTG has a market cap of 1.2B. Regarding current trading prices, AIDX is priced at $0.60, while PNTG trades at $35.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas PNTG's P/E ratio is 29.20. In terms of profitability, AIDX's ROE is +1.12%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, AIDX is more volatile compared to PNTG. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check PNTG's competition here
AIDX vs BKDT Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, AIDX is priced at $0.60, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas BKDT's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, AIDX is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check BKDT's competition here
AIDX vs USPH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, USPH has a market cap of 1B. Regarding current trading prices, AIDX is priced at $0.60, while USPH trades at $68.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas USPH's P/E ratio is 26.47. In terms of profitability, AIDX's ROE is +1.12%, compared to USPH's ROE of +0.00%. Regarding short-term risk, AIDX is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check USPH's competition here
AIDX vs TALK Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, TALK has a market cap of 874.4M. Regarding current trading prices, AIDX is priced at $0.60, while TALK trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas TALK's P/E ratio is 769.91. In terms of profitability, AIDX's ROE is +1.12%, compared to TALK's ROE of +0.01%. Regarding short-term risk, AIDX is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check TALK's competition here
AIDX vs TALKW Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, TALKW has a market cap of 869.4M. Regarding current trading prices, AIDX is priced at $0.60, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas TALKW's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, AIDX is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check TALKW's competition here
AIDX vs FSHCX Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, FSHCX has a market cap of 825.9M. Regarding current trading prices, AIDX is priced at $0.60, while FSHCX trades at $119.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas FSHCX's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to FSHCX's ROE of N/A. Regarding short-term risk, AIDX is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check FSHCX's competition here
AIDX vs SNDA Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, SNDA has a market cap of 780.4M. Regarding current trading prices, AIDX is priced at $0.60, while SNDA trades at $39.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas SNDA's P/E ratio is -7.23. In terms of profitability, AIDX's ROE is +1.12%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, AIDX is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check SNDA's competition here
AIDX vs EHAB Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, AIDX is priced at $0.60, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas EHAB's P/E ratio is -197.14. In terms of profitability, AIDX's ROE is +1.12%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, AIDX is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check EHAB's competition here
AIDX vs GMRS Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, GMRS has a market cap of 663.4M. Regarding current trading prices, AIDX is priced at $0.60, while GMRS trades at $14.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas GMRS's P/E ratio is 6.46. In terms of profitability, AIDX's ROE is +1.12%, compared to GMRS's ROE of +1.01%. Regarding short-term risk, AIDX is more volatile compared to GMRS. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check GMRS's competition here
AIDX vs TOI Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, TOI has a market cap of 538.9M. Regarding current trading prices, AIDX is priced at $0.60, while TOI trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas TOI's P/E ratio is -14.97. In terms of profitability, AIDX's ROE is +1.12%, compared to TOI's ROE of +3.27%. Regarding short-term risk, AIDX is more volatile compared to TOI. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check TOI's competition here
AIDX vs CYH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CYH has a market cap of 462.2M. Regarding current trading prices, AIDX is priced at $0.60, while CYH trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CYH's P/E ratio is 4.49. In terms of profitability, AIDX's ROE is +1.12%, compared to CYH's ROE of +0.06%. Regarding short-term risk, AIDX is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check CYH's competition here
AIDX vs VMD Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, VMD has a market cap of 445.9M. Regarding current trading prices, AIDX is priced at $0.60, while VMD trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas VMD's P/E ratio is 31.43. In terms of profitability, AIDX's ROE is +1.12%, compared to VMD's ROE of +0.11%. Regarding short-term risk, AIDX is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check VMD's competition here
AIDX vs MCTA Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, AIDX is priced at $0.60, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas MCTA's P/E ratio is 419.36. In terms of profitability, AIDX's ROE is +1.12%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, AIDX is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check MCTA's competition here
AIDX vs CCRN Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CCRN has a market cap of 427.1M. Regarding current trading prices, AIDX is priced at $0.60, while CCRN trades at $13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CCRN's P/E ratio is -188.86. In terms of profitability, AIDX's ROE is +1.12%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, AIDX is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check CCRN's competition here
AIDX vs AUNA Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AUNA has a market cap of 380.1M. Regarding current trading prices, AIDX is priced at $0.60, while AUNA trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AUNA's P/E ratio is 4.63. In terms of profitability, AIDX's ROE is +1.12%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, AIDX is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check AUNA's competition here
AIDX vs AIRS Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AIRS has a market cap of 322.4M. Regarding current trading prices, AIDX is priced at $0.60, while AIRS trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AIRS's P/E ratio is -152.33. In terms of profitability, AIDX's ROE is +1.12%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, AIDX is more volatile compared to AIRS. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check AIRS's competition here
AIDX vs CSU Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, AIDX is priced at $0.60, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CSU's P/E ratio is 0.67. In terms of profitability, AIDX's ROE is +1.12%, compared to CSU's ROE of -0.51%. Regarding short-term risk, AIDX is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check CSU's competition here
AIDX vs JYNT Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, JYNT has a market cap of 121.5M. Regarding current trading prices, AIDX is priced at $0.60, while JYNT trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas JYNT's P/E ratio is 85.20. In terms of profitability, AIDX's ROE is +1.12%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, AIDX is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check JYNT's competition here
AIDX vs NAKAW Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, AIDX is priced at $0.60, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas NAKAW's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, AIDX is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check NAKAW's competition here
AIDX vs FVE Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, AIDX is priced at $0.60, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas FVE's P/E ratio is -5.64. In terms of profitability, AIDX's ROE is +1.12%, compared to FVE's ROE of -0.15%. Regarding short-term risk, AIDX is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check FVE's competition here
AIDX vs KDLYW Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, AIDX is priced at $0.60, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas KDLYW's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, AIDX is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check KDLYW's competition here
AIDX vs BTMD Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, BTMD has a market cap of 79.4M. Regarding current trading prices, AIDX is priced at $0.60, while BTMD trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas BTMD's P/E ratio is 4.09. In terms of profitability, AIDX's ROE is +1.12%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, AIDX is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check BTMD's competition here
AIDX vs NAKA Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, NAKA has a market cap of 66.8M. Regarding current trading prices, AIDX is priced at $0.60, while NAKA trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas NAKA's P/E ratio is -0.21. In terms of profitability, AIDX's ROE is +1.12%, compared to NAKA's ROE of -0.85%. Regarding short-term risk, AIDX is more volatile compared to NAKA. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check NAKA's competition here
AIDX vs DCGO Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, DCGO has a market cap of 49.6M. Regarding current trading prices, AIDX is priced at $0.60, while DCGO trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas DCGO's P/E ratio is -0.58. In terms of profitability, AIDX's ROE is +1.12%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, AIDX is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check DCGO's competition here
AIDX vs ALR Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, AIDX is priced at $0.60, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas ALR's P/E ratio is -1.11. In terms of profitability, AIDX's ROE is +1.12%, compared to ALR's ROE of -0.15%. Regarding short-term risk, AIDX is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check ALR's competition here
AIDX vs IMAC Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, AIDX is priced at $0.60, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas IMAC's P/E ratio is -2.27. In terms of profitability, AIDX's ROE is +1.12%, compared to IMAC's ROE of +5.81%. Regarding short-term risk, AIDX is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check IMAC's competition here
AIDX vs CCEL Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CCEL has a market cap of 26.7M. Regarding current trading prices, AIDX is priced at $0.60, while CCEL trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CCEL's P/E ratio is -10.06. In terms of profitability, AIDX's ROE is +1.12%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, AIDX is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check CCEL's competition here
AIDX vs CANO-WT Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, AIDX is priced at $0.60, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, AIDX is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check CANO-WT's competition here
AIDX vs AIH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, AIDX is priced at $0.60, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AIH's P/E ratio is -2.78. In terms of profitability, AIDX's ROE is +1.12%, compared to AIH's ROE of +1.16%. Regarding short-term risk, AIDX is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check AIH's competition here
AIDX vs CANO Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, AIDX is priced at $0.60, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CANO's P/E ratio is -0.01. In terms of profitability, AIDX's ROE is +1.12%, compared to CANO's ROE of -1.49%. Regarding short-term risk, AIDX is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check CANO's competition here
AIDX vs AMS Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AMS has a market cap of 10.7M. Regarding current trading prices, AIDX is priced at $0.60, while AMS trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AMS's P/E ratio is -7.28. In terms of profitability, AIDX's ROE is +1.12%, compared to AMS's ROE of -0.06%. Regarding short-term risk, AIDX is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check AMS's competition here
AIDX vs FTRP Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, AIDX is priced at $0.60, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas FTRP's P/E ratio is -1.22. In terms of profitability, AIDX's ROE is +1.12%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, AIDX is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check FTRP's competition here
AIDX vs MODV Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, AIDX is priced at $0.60, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas MODV's P/E ratio is -0.03. In terms of profitability, AIDX's ROE is +1.12%, compared to MODV's ROE of +1.84%. Regarding short-term risk, AIDX is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check MODV's competition here
AIDX vs GBNH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, AIDX is priced at $0.60, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas GBNH's P/E ratio is -0.06. In terms of profitability, AIDX's ROE is +1.12%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, AIDX is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check GBNH's competition here
AIDX vs RHE Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, AIDX is priced at $0.60, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas RHE's P/E ratio is -1.79. In terms of profitability, AIDX's ROE is +1.12%, compared to RHE's ROE of -0.36%. Regarding short-term risk, AIDX is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check RHE's competition here
AIDX vs RHE-PA Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, AIDX is priced at $0.60, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, AIDX's ROE is +1.12%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, AIDX is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check RHE-PA's competition here
AIDX vs TOIIW Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, TOIIW has a market cap of 2.8M. Regarding current trading prices, AIDX is priced at $0.60, while TOIIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas TOIIW's P/E ratio is -0.10. In terms of profitability, AIDX's ROE is +1.12%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, AIDX is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check TOIIW's competition here
AIDX vs IMACW Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, AIDX is priced at $0.60, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas IMACW's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, AIDX is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check IMACW's competition here
AIDX vs CCM Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, CCM has a market cap of 693.1K. Regarding current trading prices, AIDX is priced at $0.60, while CCM trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas CCM's P/E ratio is -0.40. In terms of profitability, AIDX's ROE is +1.12%, compared to CCM's ROE of +0.07%. Regarding short-term risk, AIDX is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check CCM's competition here
AIDX vs NIVF Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, NIVF has a market cap of 308.4K. Regarding current trading prices, AIDX is priced at $0.60, while NIVF trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas NIVF's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, AIDX is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check NIVF's competition here
AIDX vs NIVFW Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, NIVFW has a market cap of 79.6K. Regarding current trading prices, AIDX is priced at $0.60, while NIVFW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas NIVFW's P/E ratio is -0.02. In terms of profitability, AIDX's ROE is +1.12%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, AIDX is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check NIVFW's competition here
AIDX vs MNDR Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, MNDR has a market cap of 75.3K. Regarding current trading prices, AIDX is priced at $0.60, while MNDR trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas MNDR's P/E ratio is -0.08. In terms of profitability, AIDX's ROE is +1.12%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, AIDX is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check MNDR's competition here
AIDX vs HNGR Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas HNGR's P/E ratio is 19.71. In terms of profitability, AIDX's ROE is +1.12%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, AIDX is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check HNGR's competition here
AIDX vs KND Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, KND has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas KND's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to KND's ROE of -0.53%. Regarding short-term risk, AIDX is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check KND's competition here
AIDX vs SLHGP Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, AIDX's ROE is +1.12%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, AIDX is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check SLHGP's competition here
AIDX vs AFAM Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, AFAM has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas AFAM's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, AIDX is more volatile compared to AFAM. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check AFAM's competition here
AIDX vs TLMD Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas TLMD's P/E ratio is -1.60. In terms of profitability, AIDX's ROE is +1.12%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, AIDX is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check TLMD's competition here
AIDX vs DCGOW Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas DCGOW's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, AIDX is more volatile compared to DCGOW. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check DCGOW's competition here
AIDX vs TVTY Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas TVTY's P/E ratio is 19.06. In terms of profitability, AIDX's ROE is +1.12%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, AIDX is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check TVTY's competition here
AIDX vs NFH Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, NFH has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas NFH's P/E ratio is -19.75. In terms of profitability, AIDX's ROE is +1.12%, compared to NFH's ROE of -0.06%. Regarding short-term risk, AIDX is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check NFH's competition here
AIDX vs TLMDW Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas TLMDW's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, AIDX is more volatile compared to TLMDW. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check TLMDW's competition here
AIDX vs DVCR Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas DVCR's P/E ratio is 28.34. In terms of profitability, AIDX's ROE is +1.12%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, AIDX is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for AIDX.Check DVCR's competition here
AIDX vs SLHG Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas SLHG's P/E ratio is -1.48. In terms of profitability, AIDX's ROE is +1.12%, compared to SLHG's ROE of N/A. Regarding short-term risk, AIDX is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check SLHG's competition here
AIDX vs ATIP-WT Comparison June 2026
AIDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIDX stands at 3.4M. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, AIDX is priced at $0.60, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIDX currently has a P/E ratio of -1.13, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, AIDX's ROE is +1.12%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, AIDX is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AIDX.Check ATIP-WT's competition here